0001493152-24-008897.txt : 20240305 0001493152-24-008897.hdr.sgml : 20240305 20240305172646 ACCESSION NUMBER: 0001493152-24-008897 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20240305 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240305 DATE AS OF CHANGE: 20240305 FILER: COMPANY DATA: COMPANY CONFORMED NAME: bioAffinity Technologies, Inc. CENTRAL INDEX KEY: 0001712762 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 465211056 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41463 FILM NUMBER: 24722479 BUSINESS ADDRESS: STREET 1: 22211 WEST INTERSTATE-10 STREET 2: SUITE 1206 CITY: SAN ANTONIO STATE: TX ZIP: 78257 BUSINESS PHONE: 210-698-5334 MAIL ADDRESS: STREET 1: 22211 WEST INTERSTATE-10 STREET 2: SUITE 1206 CITY: SAN ANTONIO STATE: TX ZIP: 78257 8-K 1 form8-k.htm
false 0001712762 0001712762 2024-03-05 2024-03-05 0001712762 BIAF:CommonStockParValue.007PerShareMember 2024-03-05 2024-03-05 0001712762 BIAF:TradeableWarrantsToPurchaseCommonStockMember 2024-03-05 2024-03-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): March 5, 2024

 

BIOAFFINITY TECHNOLOGIES, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-41463   46-5211056
(State or other jurisdiction
of incorporation)		   (Commission
File Number)		   (I.R.S. Employer
Identification Number)

 

22211 W Interstate 10

Suite 1206

San Antonio, Texas 78257

(210) 698-5334

(Address of principal executive offices and Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

  ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
  ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
  ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
  ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $.007 per share   BIAF   The Nasdaq Stock Market LLC
Tradeable Warrants to purchase Common Stock   BIAFW   The Nasdaq Stock Market LLC

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 2.02. Results of Operation and Financial Condition.

 

On March 5, 2024, bioAffinity Technologies, Inc., a Delaware corporation (the “Registrant”), issued a press release that included financial information for its year ended December 31, 2023. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information in this Item 2.02 and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

The following exhibit is furnished with this Current Report on Form 8-K:

 

Exhibit   Description
99.1   Press Release issued by bioAffinity Technologies, Inc. dated March 5, 2024
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: March 5, 2024

BIOAFFINITY TECHNOLOGIES, INC.

  (Registrant)
   
  By: /s/ Maria Zannes
  Name: Maria Zannes
  Title: President and Chief Executive Officer

 

 

 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

 

bioAffinity Technologies Reports Accelerating Sales Growth of CyPath® Lung

 

Increasing physician interest, newly approved reimbursement code driving growth

 

SAN ANTONIO (March 5, 2024) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer and lung disease, today reported accelerating growth of 375% in CyPath® Lung tests ordered and processed over the past three months as compared to the previous three months. CyPath® Lung is a noninvasive test to detect early-stage lung cancer.

 

bioAffinity Technologies is on target to meet its sales forecast for the previously announced limited test market launch in Texas designed to refine future positioning and strategic insight for CyPath® Lung in preparation for expanding to the national market.

 

“The introduction of our reimbursement code, completion of our branding, and expansion of our sales force have markedly contributed to the growing physician interest and adoption of our innovative, noninvasive CyPath® Lung test. Increasing physician satisfaction and adoption have also been driven by the successful integration and efficient operation of our commercial laboratory, Precision Pathology Laboratory,” bioAffinity Technologies’ President and CEO Maria Zannes said. “Importantly, our sales growth has been in line with our expectations and bolsters our confidence in our ability to capitalize on the lung cancer diagnostics market projected to reach $4.7 billion by 2030.”

 

Pulmonologists and other lung health specialists understand the critically important role of screening and early diagnosis in improving outcomes for those diagnosed with lung cancer and providing peace of mind for individuals at elevated risk of developing the disease. bioAffinity Technologies’ commitment to noninvasive cancer detection is poised to reshape the landscape of lung health management by increasing early detection and treatment.

 

bioAffinity Technologies will release financial results for the fourth quarter and full year ended December 31, 2023, on April 1, 2024.

 

About CyPath® Lung

 

CyPath® Lung uses advanced flow cytometry and artificial intelligence (AI) to identify cell populations in patient sputum that indicate malignancy. Automated data analysis helps determine if cancer is present or if the patient is cancer-free. CyPath® Lung incorporates a fluorescent porphyrin, TCPP, that is preferentially taken up by cancer and cancer-related cells. Clinical study results demonstrated that CyPath® Lung had 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in patients at high risk for the disease who had small lung nodules less than 20 millimeters. Diagnosing and treating early-stage cancer can improve outcomes and increase patient survival. 

 

 
 

 

About bioAffinity Technologies, Inc.

 

bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and broad-spectrum cancer treatments. The Company’s first product, CyPath® Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. Research and optimization of the Company’s platform technologies are conducted in its laboratories at Precision Pathology and The University of Texas at San Antonio. For more information, visit www.bioaffinitytech.com and follow us on LinkedIn, Facebook and X.

 

Forward-Looking Statements

 

Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding the Company being on target to meet its sales forecast for the previously announced limited test market launch in Texas, the Company’s ability to capitalize on the lung cancer diagnostics market projected to reach $4.7 billion by 2030 and the Company’s commitment to noninvasive cancer detection being poised to reshape the landscape of lung health management by increasing early detection and treatment. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company’s ability to continue to meet its forecast and capitalize on the lung cancer diagnostics market, and the other factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, and its subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. While the Company believes these forward-looking statements are reasonable, readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The information in this release is provided only as of the date of this release, and the Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.

 

Contacts

 

bioAffinity Technologies

 

Julie Anne Overton

Director of Communications

jao@bioaffinitytech.com

 

Investor Relations

 

Dave Gentry

RedChip Companies Inc.

1-800-RED-CHIP (733-2447) or 407-491-4498

BIAF@redchip.com

 

 

 

 GRAPHIC 3 ex99-1_001.jpg begin 644 ex99-1_001.jpg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end EX-101.SCH 4 biaf-20240305.xsd INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 5 biaf-20240305_def.xml INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 6 biaf-20240305_lab.xml INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Class of Stock [Axis] Common Stock, par value $.007 per share Tradeable Warrants to purchase Common Stock Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 7 biaf-20240305_pre.xml INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Cover
Mar. 05, 2024
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 05, 2024
Entity File Number 001-41463
Entity Registrant Name BIOAFFINITY TECHNOLOGIES, INC.
Entity Central Index Key 0001712762
Entity Tax Identification Number 46-5211056
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 22211 W Interstate 10
Entity Address, Address Line Two Suite 1206
Entity Address, City or Town San Antonio
Entity Address, State or Province TX
Entity Address, Postal Zip Code 78257
City Area Code (210)
Local Phone Number 698-5334
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
Common Stock, par value $.007 per share  
Title of 12(b) Security Common Stock, par value $.007 per share
Trading Symbol BIAF
Security Exchange Name NASDAQ
Tradeable Warrants to purchase Common Stock  
Title of 12(b) Security Tradeable Warrants to purchase Common Stock
Trading Symbol BIAFW
Security Exchange Name NASDAQ
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 3 24 1 false 2 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://bioaffinitytech.com/role/Cover Cover Cover 1 false false All Reports Book All Reports biaf-20240305.xsd biaf-20240305_def.xml biaf-20240305_lab.xml biaf-20240305_pre.xml form8-k.htm http://xbrl.sec.gov/dei/2023 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form8-k.htm": { "nsprefix": "BIAF", "nsuri": "http://bioaffinitytech.com/20240305", "dts": { "schema": { "local": [ "biaf-20240305.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "definitionLink": { "local": [ "biaf-20240305_def.xml" ] }, "labelLink": { "local": [ "biaf-20240305_lab.xml" ] }, "presentationLink": { "local": [ "biaf-20240305_pre.xml" ] }, "inline": { "local": [ "form8-k.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 0, "memberCustom": 2, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 3, "entityCount": 1, "segmentCount": 2, "elementCount": 65, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 27 }, "report": { "R1": { "role": "http://bioaffinitytech.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-03-05", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-05", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "auth_ref": [] }, "BIAF_CommonStockParValue.007PerShareMember": { "xbrltype": "domainItemType", "nsuri": "http://bioaffinitytech.com/20240305", "localname": "CommonStockParValue.007PerShareMember", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Common Stock, par value $.007 per share" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "auth_ref": [] }, "BIAF_TradeableWarrantsToPurchaseCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://bioaffinitytech.com/20240305", "localname": "TradeableWarrantsToPurchaseCommonStockMember", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Tradeable Warrants to purchase Common Stock" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 17 0001493152-24-008897-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-24-008897-xbrl.zip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end XML 18 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001712762 2024-03-05 2024-03-05 0001712762 BIAF:CommonStockParValue.007PerShareMember 2024-03-05 2024-03-05 0001712762 BIAF:TradeableWarrantsToPurchaseCommonStockMember 2024-03-05 2024-03-05 iso4217:USD shares iso4217:USD shares false 0001712762 8-K 2024-03-05 BIOAFFINITY TECHNOLOGIES, INC. DE 001-41463 46-5211056 22211 W Interstate 10 Suite 1206 San Antonio TX 78257 (210) 698-5334 false false false false true Common Stock, par value $.007 per share BIAF NASDAQ Tradeable Warrants to purchase Common Stock BIAFW NASDAQ false